# MK0524B Bioequivalence Study (0524B-070)

> **NCT00943124** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 220 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** MK0524B (ER niacin (+) laropiprant (+) simvastatin)
- **DRUG:** MK0524A (ER niacin + laropiprant)
- **DRUG:** Simvastatin

## Key facts

- **NCT ID:** NCT00943124
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2015-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00943124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00943124, "MK0524B Bioequivalence Study (0524B-070)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00943124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*